全文获取类型
收费全文 | 2986篇 |
免费 | 385篇 |
国内免费 | 74篇 |
专业分类
儿科学 | 35篇 |
妇产科学 | 3篇 |
基础医学 | 31篇 |
口腔科学 | 1篇 |
临床医学 | 193篇 |
内科学 | 2242篇 |
神经病学 | 4篇 |
特种医学 | 166篇 |
外国民族医学 | 2篇 |
外科学 | 269篇 |
综合类 | 260篇 |
现状与发展 | 1篇 |
预防医学 | 12篇 |
药学 | 37篇 |
中国医学 | 24篇 |
肿瘤学 | 165篇 |
出版年
2024年 | 3篇 |
2023年 | 140篇 |
2022年 | 207篇 |
2021年 | 382篇 |
2020年 | 355篇 |
2019年 | 323篇 |
2018年 | 272篇 |
2017年 | 156篇 |
2016年 | 134篇 |
2015年 | 193篇 |
2014年 | 215篇 |
2013年 | 193篇 |
2012年 | 105篇 |
2011年 | 110篇 |
2010年 | 88篇 |
2009年 | 71篇 |
2008年 | 74篇 |
2007年 | 51篇 |
2006年 | 65篇 |
2005年 | 61篇 |
2004年 | 31篇 |
2003年 | 34篇 |
2002年 | 26篇 |
2001年 | 35篇 |
2000年 | 20篇 |
1999年 | 15篇 |
1998年 | 22篇 |
1997年 | 8篇 |
1996年 | 9篇 |
1995年 | 11篇 |
1994年 | 7篇 |
1993年 | 8篇 |
1992年 | 2篇 |
1991年 | 3篇 |
1990年 | 3篇 |
1989年 | 4篇 |
1988年 | 3篇 |
1987年 | 1篇 |
1985年 | 1篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1981年 | 1篇 |
排序方式: 共有3445条查询结果,搜索用时 15 毫秒
101.
Orthodeoxia-platypnea due to intracardiac shunting relief with transcatheter double umbrella closure
Michael J. Landzberg Laurence J. Sloss Chris E. Faherty Brian J. Morrison John A. Bittl Nancy D. Bridges Paul N. Casale John F. Keane James E. Lock 《Catheterization and cardiovascular interventions》1995,36(3):247-250
The safety and efficacy of transcatheter clamshell occlusion of patent foramen ovale for relief of severe arterial desaturation and dyspnea in the upright position due to intracardiac shunting were examined in eight patients with excessive risk of surgical patent foramen ovale closure. All patients had successful reduction of intracardiac shunting with an immediate rise in oxygen saturation ?95% by implantation of a clamshell device on the atrial septum. Despite two early incidents of device embolization, retrieval and immediate re-implantation, and one patient with nonsustained atrial and ventricular arrhythmias, there were no adverse clinical sequelae. In follow-up evaluation transcatheter clamshell closure of patent foramen ovale has provided persistent relief from shuntrelated arterial desaturation and symptomatology in all living patients. © 1995 Wiley-Liss, Inc. 相似文献
102.
Victor Alfonso Jimenez Diaz Antonio Tello-Montoliu Raul Moreno Ignacio Cruz Gonzalez Jose Antonio Baz Alonso Rafael Romaguera Eduardo Molina Navarro Pablo Juan Salvadores Emilio Paredes Galan Antonio De Miguel Castro Guillermo Bastos Fernandez Alberto Ortiz Saez Saleta Fernandez Barbeira Sergio Raposeiras Roubin Juan Ocampo Miguez Antonio Serra Peñaranda Mariano Valdes Chavarri Angel Cequier Fillat Andres Iñiguez Romo 《JACC: Cardiovascular Interventions》2019,12(1):22-32
Objectives
The REAC-TAVI (Assessment of platelet REACtivity after Transcatheter Aortic Valve Implantation) trial enrolled patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) pre-treated with aspirin + clopidogrel, aimed to compare the efficacy of clopidogrel and ticagrelor in suppressing high platelet reactivity (HPR) after TAVI.Background
Current recommendations support short-term use of aspirin + clopidogrel for patients with severe AS undergoing TAVR despite the lack of compelling evidence.Methods
This was a prospective, randomized, multicenter investigation. Platelet reactivity was measured at 6 different time points with the VerifyNow assay (Accriva Diagnostics, San Diego, California). HPR was defined as (P2Y12 reaction units (PRU) ≥208. Patients with HPR before TAVR were randomized to either aspirin + ticagrelor or aspirin + clopidogrel for 3 months. Patients without HPR continued with aspirin + clopidogrel (registry cohort). The primary endpoint was non-HPR status (PRU <208) in ≥70% of patients treated with ticagrelor at 90 days post-TAVR.Results
A total of 68 patients were included. Of these, 48 (71%) had HPR (PRU 273 ± 09) and were randomized to aspirin + ticagrelor (n = 24, PRU 277 ± 08) or continued with aspirin + clopidogrel (n = 24, PRU 269 ± 49). The remaining 20 patients (29%) without HPR (PRU 133 ± 12) were included in the registry. Overall, platelet reactivity across all the study time points after TAVR was lower in patients randomized to ticagrelor compared with those treated with clopidogrel, including those enrolled in the registry (p < 0.001). The primary endpoint was achieved in 100% of patients with ticagrelor compared with 21% with clopidogrel (p < 0.001). Interestingly, 33% of clopidogrel responder patients at baseline developed HPR status during the first month after TAVR.Conclusions
HPR to clopidogrel is present in a considerable number of patients with AS undergoing TAVR. Ticagrelor achieves a better and faster effect, providing sustained suppression of HPR to these patients. (Platelet Reactivity After TAVI: A Multicenter Pilot Study [REAC-TAVI]; NCT02224066) 相似文献103.
《JACC: Cardiovascular Imaging》2022,15(11):1843-1851
BackgroundAmong patients with severe functional mitral regurgitation (FMR), atrial functional mitral regurgitation (aFMR) represents an underrecognized entity. Data regarding outcomes after mitral valve transcatheter edge-to-edge repair (M-TEER) in aFMR remain scarce.ObjectivesThe objective of this study was to analyze the outcome of aFMR patients undergoing M-TEER.MethodsUsing patients from the international EuroSMR (European Registry of Transcatheter Repair for Secondary Mitral Regurgitation) registry undergoing M-TEER for FMR, the authors analyzed baseline characteristics and 2-year outcomes in aFMR in comparison to non-aFMR and ventricular FMR. Additionally, the impact of right ventricular dysfunction (RVD) (defined as right ventricular to pulmonary artery uncoupling) on outcome after M-TEER was assessed.ResultsAmong 1,608 FMR patients treated by M-TEER, 126 (7.8%) were categorized as aFMR. All 126 aFMR patients had preserved left ventricular function without regional wall motion abnormalities, left arterial dilatation and Carpentier leaflet motion type I. Procedural success (defined as mitral regurgitation ≤2+ at discharge) was 87.2% (P < 0.001) and New York Heart Association (NYHA) functional class significantly improved during follow-up (NYHA functional class III/IV: 86.5% at baseline to 36.6% at follow-up; P < 0.001). The estimated 2-year survival rate in aFMR patients was 70.4%. Two-year survival did not differ significantly between aFMR, non-aFMR, and ventricular FMR. Besides NYHA functional class IV, RVD was identified as a strong independent predictor for 2-year survival (HR: 2.82 [95% CI: 1.24-6.45]; P = 0.014).ConclusionsaFMR is a frequent cause of FMR and can be effectively treated with M-TEER to improve symptoms at follow-up. Advanced heart failure symptoms and RVD were identified as important risk factors for survival in aFMR patients. 相似文献
104.
105.
Tatsuya Seki Mamoru Sakakibara Yasushige Shingu Hiroki Katoh Satoru Wakasa Hiroyuki Tsutsui Yoshiro Matsui 《Annals of thoracic and cardiovascular surgery》2015,21(2):132-138
Purpose: Transcatheter aortic valve replacement (TAVR) has emerged as a therapeutic option for severe aortic valvular stenosis (AS). To determine the indication for TAVR, it is mandatory to clarify the characteristics of the patients who were judged as inoperable for conventional aortic valve replacement (cAVR).Methods: Of 185 patients newly diagnosed as severe AS from March 2010 to April 2011, we studied the characteristics of 61 (33%) patients (mean age, 86 ± 8 years) who were judged as inoperable.Results: Younger patients (<85 years old, n = 22) had more major comorbidities and lower left ventricular ejection fraction than older patients (≥85 years old, n = 39). Mean estimated mortality for cAVR by Japan score was 7.0% ± 7.4%. Japan score did not correlate to age and was calculated relatively low in the older age group (6.2% ± 7.0%) than the younger age group (8.3% ± 8.1%).Conclusion: One thirds of severe AS patients were judged as inoperable. In advanced age patients, age itself and other factors, which are not included in the conventional scoring systems, might have contributed to the decision making not to perform cAVR by cardiologists. Further study is necessary to define risk factors except for age. 相似文献
106.
Brunilda Alushi Frederik Beckhoff David Leistner Marcus Franz Markus Reinthaler Barbara E. Stähli Andreas Morguet Hans R. Figulla Torsten Doenst Francesco Maisano Volkmar Falk Ulf Landmesser Alexander Lauten 《JACC: Cardiovascular Imaging》2019,12(4):591-601
Objectives
The authors investigated the development of pulmonary hypertension (PH), predictors of PH regression, and its prognostic impact on short, mid-, and long-term outcomes in patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS).Background
PH represents a common finding in patients with AS. Although TAVR is frequently associated with regression of PH, the predictors of reversible PH and its prognostic significance remain uncertain.Methods
In this study, 617 consecutive patients undergoing TAVR between 2009 and 2015 were stratified per baseline tertiles of pulmonary artery systolic pressure (PASP) as follows: normal (PASP <34 mm Hg), mild-to-moderate (PASP ≥34 mm Hg and <46 mm Hg), and severe PASP elevation (PASP ≥46 mm Hg). After TAVR, 520 patients with PH at discharge were stratified according to the presence or absence of PASP reduction. Primary outcome was all-cause mortality at 30 days, 1 year, and long-term follow-up at a maximum of 5.9 years.Results
In patients with both mild-to-moderate and severe PH at baseline, PASP decreased significantly at discharge (ΔPASP 3.0 ± 9.3 mm Hg and 12.0 ± 10.0 mm Hg, respectively) and 1 year (ΔPASP 5.0 ± 9.7 mm Hg and 18.0 ± 14.0 mm Hg, respectively). At a median follow-up of 370 days (interquartile range [IQR]: 84 to 500 days), the risk of all-cause mortality was similar among baseline PASP groups at all time intervals evaluated. After TAVR, a significant regression of PH was observed in 46% of patients. Contrarily, patients with residual PH had a higher risk of all-cause mortality at 30 days (hazard ratio [HR]: 3.49, 95% confidence interval [CI]: 1.74 to 6.99; p < 0.001), 1 year (HR: 3.12, 95% CI: 2.06 to 4.72; p < 0.001), and long-term (HR: 2.47, 95% CI: 1.74 to 3.49; p < 0.001). Left ventricular ejection fraction (LVEF) >40% (odds ratio [OR]: 3.56, 95% CI: 2.24 to 5.65; p < 0.001), baseline PASP ≥46 mm Hg (OR: 3.26, 95% CI: 2.07 to 5.12; p < 0.001), absence of concomitant tricuspid regurgitation (TR) ≥ moderate (OR: 0.53, 95% CI: 0.34 to 0.84; p < 0.001), and logistic EuroSCORE <25% (OR: 1.59, 95% CI: 1.04 to 2.45; p = 0.03) were independent predictors of PASP reduction.Conclusions
In most patients with PH and AS, TAVR is associated with a significant early and late reduction of PASP. Patients with reversible PH after TAVR are at lower risk of all-cause mortality at early, mid-, and long-term follow-up. Therefore, the presence of PH should not preclude treatment with TAVR. 相似文献107.
Sanjay Sinha Asra Khan Athar M. Qureshi William Suh Hillel Laks Jamil Aboulhosn Reshma Biniwale Iki Adachi Anisha Fernando Daniel Levi 《Catheterization and cardiovascular interventions》2020,95(2):253-261
- Diabetic patients are frequently affected by coronary artery disease (CAD) and are at increased risk of CAD‐related adverse events, even after drug‐eluting stent (DES) implantation. If currently available DES have similar safety and efficacy in diabetic and nondiabetic patients is still debated.
- This prospective, multicenter registry showed similar 3‐year outcome in patients undergoing different DES implantation, although diabetic patients, especially those requiring insulin treatment, had significantly higher risk of adverse events than nondiabetic patients.
- Specific efforts to improve the performance of DES in diabetic patients are mandatory to adequately address the unsolved issue of diabetic patients affected by CAD.
108.
109.
110.
Transcatheter valve‐in‐ring implantation after a failed surgical mitral repair using a transseptal approach and a veno‐arterial loop for valve placement 下载免费PDF全文
Hüseyin Ince MD PhD Ilkay Bozdağ‐Turan MD 《Catheterization and cardiovascular interventions》2014,84(7):1202-1208
A failure of a mitral valve repair, which includes the implantation of a mitral annuloplasty ring in the majority of cases, is associated with relevant mortality. Surgery is considered as the standard treatment for these patients. For patients who have an unacceptable high peri‐surgical risk a transcatheter valve‐in‐ring (TVIR) procedure might be an option. Isolated case reports and small case series report on the feasibility of a TVIR implantation in mitral position. We present a case where a 29‐mm Edwards Sapien valve was placed in a 32‐mm Carpentier Edwards ring. To our knowledge no valve has been implanted so far in this ring size and this is the first case where a veno‐arterial loop was used as guide rail for valve implantation and helped considerably to position the valve properly. © 2013 Wiley Periodicals, Inc. 相似文献